Literature DB >> 26955217

Prone position and pressure control inverse ratio ventilation in H1N1 patients with severe acute respiratory distress syndrome.

Pradeep M Venkategowda1, S Manimala Rao1, Yogesh R Harde1, Mithilesh K Raut1, Dnyaneshwar P Mutkule1, Kartik Munta1, Mallela V Rao2.   

Abstract

AIM: To observe the 28 and 90 days mortality associated with prone position and assist control-pressure control (with inverse ratio) ventilation (ACPC-IRV).
MATERIALS AND METHODS: All patients who were admitted to our medical Intensive Care Unit (ICU) who are positive for H1N1 viral infection with severe acute respiratory distress syndrome (ARDS) and requiring invasive mechanical ventilation in prone position were included in our prospective observational study. Six patients who are positive for H1N1 required invasive ventilation in prone position. These patients were planned to ventilate in prone for 16 h and in supine for 8 h daily until P/F ratio >150 with FiO2 of 0.6 or less and positive end-expiratory pressure <10 cm of H2 O.
RESULTS: At admission, among these six patients the mean tidal volume generated was about 376.6 ml which was in the range of 6-8 ml/kg predicted body weight. The mean lung injury score was 3.79, mean PaO2 /FiO2 ratio was 52.66 and mean oxygenation index was 29.83. The mean duration of ventilation was 9.4 days (225.6 h). The ICU length of stay was 11.16 days. There was no mortality at 28 and 90 days.
CONCLUSION: Early prone combined with ACPC-IRV in H1N1 patients having severe ARDS can be used as a rescue therapy and it should be confirmed by large observational studies.

Entities:  

Keywords:  Influenza A virus; inverse ratio ventilation; pressure control ventilation; prone position; severe acute respiratory distress syndrome

Year:  2016        PMID: 26955217      PMCID: PMC4759994          DOI: 10.4103/0972-5229.173690

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


Introduction

Acute respiratory distress syndrome (ARDS) is a complex syndrome with varied etiology. Influenza viral infection causing severe ARDS is one of the leading causes of increased mortality in the recent years. First case of H1N1 infection was reported by central of disease control in California – April 2009[1] and in India it was reported in Hyderabad – May 2009.[2] Most patients who die due to influenza infection are because of severe hypoxia and multi-organ dysfunction syndrome (MODS). In 2009 influenza pandemic, there was high mortality in patients with severe ARDS even though patients were ventilated with low tidal volume (volume control) ventilation. Multiple ventilation strategies and rescue therapies have been used to improve oxygenation. Low tidal volume ventilation (volume control) with prone position – PROSEVA trial has shown good outcome as compared to low tidal volume ventilation (volume control) with supine position.[3] In our institution we commonly practice assist control-pressure control with inverse ratio ventilation (ACPC-IRV) for ventilating severe ARDS patients. In our study we combined this ventilation strategy along with prone positioning as a rescue therapy, when the normal supine position and ACPC-IRV failed to improve oxygenation after 12 h of initiation of ventilation.

Materials and Methods

During study period between June 2014 and February 2015, 43 patients were positive for nasopharyngeal or throat swab reverse transcriptase - polymerase chain reaction[4] for H1N1 and only 17 patient's required invasive ventilatory support (ACPC-IRV). Out of 17 patients, 11 patients showed improvement in terms of oxygenation with regular supine ventilation at the end of 12 h (that is requiring FiO2 <0.6 or less, P/F ratio > 150 and positive end-expiratory pressure (PEEP) <10 cm of H2 O) and hence continued the same supine ventilation. Table 1 showing the P/F ratio and Intensive Care Unit (ICU) length of stay between prone and supine ventilated patients.
Table 1

The PaO2/FiO2 ratio and Intensive Care Unit length of stay between prone and supine ventilated patients

Six patients didn′t show any improvement after 12 h from the commencement of invasive ventilation in supine and hence they were considered for either prone ventilation/extracorporeal membrane oxygenation (ECMO) as salvageable therapy. The PaO2/FiO2 ratio and Intensive Care Unit length of stay between prone and supine ventilated patients Prone ventilation or ECMO therapy consent was initiated between 12 and 36 h of admission to medical ICU for those six patients who didn′t improve with normal pressure control with inverse ratio and supine ventilation (1:1 ratio). All six patient attendees agreed for prone ventilation as a salvage therapy and also ethics committee clearance was taken. These patients were planned to prone for 16 h and supine ventilation for 8 h daily till patient is able to maintain a P/F ratio >150 with FiO2 of 0.6 or less and PEEP <10 cm of H2 O. We followed these six patients who underwent prone ventilation till their hospital stay and followed later up to 90 days.

Results

Table 2 shows the demographic data of these six patients. Among these patients, there were four males and two females. The mean age was 46.16 years. Two patients did not had any co morbidities, where as three patients had only hypertension and remaining one patient had diabetes and hypothyroidism along with hypertension. The mean duration of fever to hospital admission was 6 days.
Table 2

Demographic profile of 6 prone ventilated patients

Demographic profile of 6 prone ventilated patients All these six patients had fever, cough and dyspnoea where as generalized weakness, nausea, vomiting and mean arterial pressure (MAP) <65 mmHg were seen in four patients. Other less common clinical features are headache, bradycardia, pleuritic chest pain and diarrhoea. The mean hemoglobin was 10.93 g/dl and total leucocyte count – 5350 cells/cumm. The serum electrolytes, liver function tests and renal function tests, prothrombin time, International Normalized Ratio and activated partial thromboplastin time were in normal range. The ventilator setting at the initiation of ventilation has been showed in Table 3. All six patients were intubated and connected to the ACPC-IRV. The mean tidal volume generated was about 376.6 ml which was in the range of 6–8 ml/kg predicted body weight at the beginning. The Inspiratory: Expiratory (I: E) ratio was initially kept 1:1 and later modified according to the PaO2 values (maximum was 2:1). The mean inspiratory pressure (Pi) was 20.66 cm H2 O, which was kept to achieve a tidal volume of 6–8 ml/kg predicted body weight and later reduced to about 6 ml/kg predicted body weight. The PEEP of 14 cm H2 O was kept initially and later reduced based on oxygenation parameter (never used more than 14 PEEP). The mean frequency and fraction of inspired oxygen were 31 breaths/min and 0.96 respectively. Figure 1 showing patient being ventilated in prone position.
Table 3

Ventilator settings of 6 prone ventilated patients at admission

Figure 1

Chest X-ray of our first patient having severe acute respiratory distress syndrome due to H1N1 infection

Ventilator settings of 6 prone ventilated patients at admission Chest X-ray of our first patient having severe acute respiratory distress syndrome due to H1N1 infection Table 4 shows the oxygenation parameters at admission. The mean lung injury score (LIS) was 3.79, mean PaO2 /FiO2 ratio was 52.66 and mean oxygenation index was 29.83. All six patients were proned for 16 h each day. The mean duration from ICU admission to initiation of prone ventilation was 30.66 h. The mean duration of ventilation was 9.4 days (225.6 h). The mean duration of prone and supine ventilation was 66.66 and 159.6 h respectively. The ICU length of stay was 11.16 days. There was no mortality at 28 and 90 days.
Table 4

Oxygenation parameters of 6 prone ventilated patients at admission

Oxygenation parameters of 6 prone ventilated patients at admission The management and complications have been shown in Table 5. Capsule oseltamivir 150 mg twice daily was used for 10 days in view of severe infection. We used tablet prednisolone 40 mg twice daily for 5 days. Patients were sedated and paralyzed using midazolam and atracurium for 2 days and later tapered slowly (average duration of 4.16 days). Vitamin-C (10 days) and omega-3 fatty acids (3 days) were also used in all six patients. Four patients required noradrenalin infusion and one patient vasopressin infusion to maintain MAP > 65 mmHg. Two patients had severe left ventricular dysfunction (myocarditis) and managed with dobutamine infusion. Orciprenalin was used in two patients for 7 days (10 mg thrice daily) in view of bradycardia. Due to prolonged ventilation required in two patients, they were tracheostomised and later successfully decannulated. With regards to complication, ventilator associated pneumonia was seen in two patients, acute kidney injury in two patients, myocarditis in two patients, critical illness myopathy and atrial fibrillation in one patient each. None of our patients had pneumothorax.
Table 5

Management and complications occurred during Intensive Care Unit stay

Management and complications occurred during Intensive Care Unit stay

Discussion

Low tidal volume ventilation (ARDS network trial) has shown better outcome in patients having severe ARDS.[5] There is still confusion regarding which rescue mode is best among available treatment. Recently prone position and low tidal volume ventilation has shown better mortality benefit as compared to supine position and low tidal volume ventilation. Combination of pressure control and IRV has been used less frequently for severe ARDS ventilation. In our ICU we commonly practice ACPC-IRV for ventilating a patient with severe ARDS. In our study population we used pressure control mode with IRV along with prone positioning [Figure 2] as a rescue therapy in H1N1 patients with severe ARDS who failed the initial ACPC-IRV.
Figure 2

Patient being ventilated in prone position

Prone ventilation has been used as one of the rescue therapy in patients having severe hypoxia related to severe ARDS. Recent study by Guιrin et al.[3] have shown that prone ventilation in severe ARDS has better outcome compared to supine ventilation with significantly decreased in 28 and 90 day mortality. Patient being ventilated in prone position The prone position has been used in severe ARDS patients since 1974 for improvement in oxygenation. Maximum improvement has been seen in patient having severe hypoxemia. Multiple mechanisms are involved in improvement of systemic oxygenation during prone ventilation such as, reduction of compression of caudal lung by cardiac and abdominal contents, reinflation of more dorsal lung compared to ventral lung, diaphragm shape, changes in hypoxic pulmonary vasoconstriction and differential production of nitric oxide at different parts of the lung. Prone positioning has shown to cause more homogenous lung inflation with reduction in ventilator induced lung injury. Richter et al.[6] showed that prone or steep lateral decubitus position can decrease intrapulmonary shunt and improve oxygenation. Prone-supine study-1[7] used 6 h of prone position daily for 10 days showed no difference in terms of mortality and complication as compared to conventional ventilation. Gattinoni et al.[8] showed that during prone ventilation, the reduction in partial pressure of carbon dioxide of 1 mm hg or more showed increase in survival rate. Prone-supine study-2[9] 20 h of prone ventilation per day also showed similar mortality at 28 days as compared to supine group and more complication in prone group. Systemic review[10] showed no reduction in mortality or duration of ventilation but only improvement in oxygenation. Hence this prone position can be used as rescue strategy to improve oxygenation. A review of all meta analyses[11] showed reduced mortality in patients with severe hypoxemia. Recently PROSEVA trial[3] has shown significant reduction in 28 and 90 days mortality when prolonged prone positioning (16 h of prone per day) in severe ARDS patients as compared to conventional ventilation. In our observational study we also used prone positioning for 16 h per day without any mortality at 28 and 90 days. Six patients didn′t show any improvement with ACPC-IRV and hence they were considered for either prone ventilation or ECMO as salvageable therapy. Figure 1 showing chest X-ray of our first patient with severe ARDS. These patients were planned to prone for 16 h and supine ventilation for 8 h in total 24 h. Only supine ventilation was maintained when patient is able to maintain P/F ratio >150 with FiO2 of 0.6 or less and PEEP <10 cm of H2 O. In our study group the mean age was 46.16 years (males-4 and females-2). Hypertension was seen among 4 of 6 patients included in the study. Most common clinical features are fever, cough and dyspnoea followed by generalized weakness, nausea, vomiting, MAP <65 mmHg, headache, bradycardia, pleuritic chest pain and diarrhoea. The mean duration of fever to hospital admission was 6 days. The ventilator setting has been showed in Table 3. The mean tidal volume generated was about 376.6 ml which was in the range of 6-8 ml/kg predicted body weight. The I: E ratio was initially kept 1:1 and to a maximum of 2:1. The mean Pi was 20.66 cm H2 O. The maximum PEEP of 14 cm H2 O was kept initially and later reduced based on oxygenation parameter. The mean frequency and fraction of inspired oxygen were 31 breaths/min and 0.96 respectively. The severity of ARDS and duration of ventilation is shown in Table 4. The mean LIS was 3.79, PaO2 /FiO2 ratio: 52.66 and mean oxygenation index: 29.83. The mean duration from ICU admission to initiation of prone ventilation was 30.66 h. The mean duration of ventilation was 9.4 days (225.6 h). The mean duration of prone and supine ventilation was 66.66 and 159.6 h respectively. All six patients were treated with capsule oseltamivir 150 mg twice daily for 10 days since our patients had severe infection with MODS, we used the double dose as recommended by WHO. Tablet prednisolone 40 mg twice daily for 5 days was used. The role of steroids in management of H1N1 related ARDS is controversial. Few studies[1213] suggest that early and low dose corticosteroids are inefficient and may be even harmful where as others[1415] have shown the improvement in LIS and hemodynamic stability. Broad spectrum antibiotics (deescalated later after bronchoalveolar lavage fluid culture and sensitivity) along with Vitamin-C (10 days) and omega-3 fatty acids (3 days) were also used during management of these patients. All patients were sedated and paralysed using midazolam and atracurium for 2 days and later tapered slowly (average duration of 4.16 days). Four patients required noradrenalin infusion and one patient vasopressin infusion to maintain MAP > 65 mmHg. Two patients had severe left ventricular dysfunction (myocarditis) and managed with dobutamine infusion. Orciprenalin was used in two patients for 7 days (10 mg thrice daily) in view of bradycardia. The ICU mortality of H1N1 patients with severe ARDS is about 10-38% and increases up to 58% in patients requiring invasive mechanical ventilation.[16] Sahoo et al.[17] in their study shown that out of seven patients, five patients had MODS. The commonest organ involved was renal. In our study acute kidney injury was seen in two patients but recovered without any need of dialysis. Ventilator associated pneumonia was seen in two patients (acenetobacter was found in both patients), myocarditis in two patients, critical illness myopathy and atrial fibrillation in one patient each. None of our patients had pneumothorax (probably due to maintenance of lower tidal volume and lesser PEEP). Figure 3 showing chest X-ray of the same patient at the end of prone ventilation on 6th day.
Figure 3

Chest X-ray of the same patient at the end of prone ventilation on 6th day

Chest X-ray of the same patient at the end of prone ventilation on 6th day The ICU length of stay depends upon severity of infection, preexisting comorbidities, BMI > 30, co-infection and MODS.[18] The mean ICU length of stay in our patients was 11.16 days. There was no mortality at 28 and 90 days.

Conclusion

Early prone combined with ACPC-IRV in H1N1 patients having severe ARDS can be used as a rescue therapy for better outcome and it should be confirmed by large observational studies.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  16 in total

Review 1.  Effect of mechanical ventilation in the prone position on clinical outcomes in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis.

Authors:  Sachin Sud; Maneesh Sud; Jan O Friedrich; Neill K J Adhikari
Journal:  CMAJ       Date:  2008-04-22       Impact factor: 8.262

2.  Prone positioning in severe acute respiratory distress syndrome.

Authors:  Claude Guérin; Jean Reignier; Jean-Christophe Richard; Pascal Beuret; Arnaud Gacouin; Thierry Boulain; Emmanuelle Mercier; Michel Badet; Alain Mercat; Olivier Baudin; Marc Clavel; Delphine Chatellier; Samir Jaber; Sylvène Rosselli; Jordi Mancebo; Michel Sirodot; Gilles Hilbert; Christian Bengler; Jack Richecoeur; Marc Gainnier; Frédérique Bayle; Gael Bourdin; Véronique Leray; Raphaele Girard; Loredana Baboi; Louis Ayzac
Journal:  N Engl J Med       Date:  2013-05-20       Impact factor: 91.245

3.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.

Authors:  Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

Review 4.  Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.

Authors:  B M Cesana; P Antonelli; D Chiumello; L Gattinoni
Journal:  Minerva Anestesiol       Date:  2010-11       Impact factor: 3.051

5.  Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome.

Authors:  Christian Brun-Buisson; Jean-Christophe M Richard; Alain Mercat; Anne C M Thiébaut; Laurent Brochard
Journal:  Am J Respir Crit Care Med       Date:  2011-03-04       Impact factor: 21.405

6.  Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores.

Authors:  Sung-Han Kim; Sang-Bum Hong; Sung-Choel Yun; Won-Il Choi; Jong-Joon Ahn; Young Joo Lee; Heung-Bum Lee; Chae-Man Lim; Younsuck Koh
Journal:  Am J Respir Crit Care Med       Date:  2011-03-04       Impact factor: 21.405

7.  Decrease in PaCO2 with prone position is predictive of improved outcome in acute respiratory distress syndrome.

Authors:  Luciano Gattinoni; Federica Vagginelli; Eleonora Carlesso; Paolo Taccone; Valeria Conte; Davide Chiumello; Franco Valenza; Pietro Caironi; Antonio Pesenti
Journal:  Crit Care Med       Date:  2003-12       Impact factor: 7.598

8.  Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-04-24       Impact factor: 17.586

9.  Critical care services and 2009 H1N1 influenza in Australia and New Zealand.

Authors:  Steven A R Webb; Ville Pettilä; Ian Seppelt; Rinaldo Bellomo; Michael Bailey; David J Cooper; Michelle Cretikos; Andrew R Davies; Simon Finfer; Peter W J Harrigan; Graeme K Hart; Belinda Howe; Jonathan R Iredell; Colin McArthur; Imogen Mitchell; Siouxzy Morrison; Alistair D Nichol; David L Paterson; Sandra Peake; Brent Richards; Dianne Stephens; Andrew Turner; Michael Yung
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

10.  Pandemic (H1N1) 2009 influenza: Experience from a critical care unit in India.

Authors:  Jyoti N Sahoo; Banani Poddar; Afzal Azim; Ratender K Singh; Mohan Gurjar; Arvind K Baronia
Journal:  Indian J Crit Care Med       Date:  2010-07
View more
  1 in total

1.  Prone ventilation in H1N1 virus-associated severe acute respiratory distress syndrome: A case series.

Authors:  Jyoti Narayan Sahoo; Mohan Gurjar; Krantimaya Mohanty; Kalpana Majhi; G Sradhanjali
Journal:  Int J Crit Illn Inj Sci       Date:  2019-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.